Treating osteogenesis imperfecta by inhibiting the PRC2 complex
Research Grant Recipient: David Deyle, MD
Award Value: $250,000
Research Focus: Skeletal regeneration, brittle bone disease
From the investigator:
The goal of this proposal is to develop a new strategy for skeletal regeneration in patients who have osteogenesis imperfecta (OI) or brittle bone disease using epigenetics regulators that alter gene expression. We have shown that inhibiting a epigenetic regulator, PCR2, increases bone formation in normal mice and will determine if this also occurs in OI mice. We will also investigate if a small molecule that inhibits the PRC2 complex can also increase bone formation in OI mice and cells from OI patients.